{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:15:25Z","timestamp":1783124125687,"version":"3.54.6"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00228-024-03746-x","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T16:02:36Z","timestamp":1724947356000},"page":"1819-1828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Fixed parameters in the population pharmacokinetic modeling of valproic acid might not be suitable: external validation in Chinese adults with epilepsy or after neurosurgery"],"prefix":"10.1007","volume":"80","author":[{"given":"Ruoyun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"issue":"10","key":"3746_CR1","doi-asserted-by":"publisher","first-page":"926","DOI":"10.2174\/1570159x17666181227165722","volume":"17","author":"M Romoli","year":"2019","unstructured":"Romoli M, Mazzocchetti P, D\u2019Alonzo R, Siliquini S, Rinaldi VE, Verrotti A, Calabresi P, Costa C (2019) Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol 17(10):926\u2013946. https:\/\/doi.org\/10.2174\/1570159x17666181227165722","journal-title":"Curr Neuropharmacol"},{"key":"3746_CR2","doi-asserted-by":"publisher","unstructured":"Global, regional, and national burden of neurological disorders (2019) 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18 (5): 459\u2013480. https:\/\/doi.org\/10.1016\/s1474-4422(18)30499-x","DOI":"10.1016\/s1474-4422(18)30499-x"},{"issue":"1","key":"3746_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12883-015-0494-y","volume":"15","author":"K Allers","year":"2015","unstructured":"Allers K, Essue BM, Hackett ML, Muhunthan J, Anderson CS, Pickles K, Scheibe F, Jan S (2015) The economic impact of epilepsy: a systematic review. BMC Neurol 15(1):245. https:\/\/doi.org\/10.1186\/s12883-015-0494-y","journal-title":"BMC Neurol"},{"key":"3746_CR4","doi-asserted-by":"publisher","unstructured":"Devinsky O, Vezzani A, O'Brien TJ, Jette N, Scheffer IE, de Curtis M, Perucca P (2018) Epilepsy. Nature Reviews Disease Primers 4. https:\/\/doi.org\/10.1038\/nrdp.2018.24","DOI":"10.1038\/nrdp.2018.24"},{"issue":"8","key":"3746_CR5","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1177\/10600280211055508","volume":"56","author":"J Guo","year":"2022","unstructured":"Guo J, Ma J, Wang S, Li X, Ji H, Li Y, Peng F, Sun Y (2022) Valproic acid after neurosurgery induces elevated risk of liver injury: a prospective nested case-control study. Ann Pharmacother 56(8):888\u2013897. https:\/\/doi.org\/10.1177\/10600280211055508","journal-title":"Ann Pharmacother"},{"issue":"12","key":"3746_CR6","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/j.1552-4604.1997.tb04301.x","volume":"37","author":"E Yukawa","year":"1997","unstructured":"Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T (1997) Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol 37(12):1160\u20131167. https:\/\/doi.org\/10.1002\/j.1552-4604.1997.tb04301.x","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"3746_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/(SICI)1099-081X(199907)20:5<233::AID-BDD179>3.0.CO;2-5","volume":"20","author":"B Blanco-Serrano","year":"1999","unstructured":"Blanco-Serrano B, Otero M, Santos-Buelga D, Garc\u00eda-S\u00e1nchez M, Serrano J, Dom\u00ednguez-Gil A (1999) Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos 20(5):233\u2013240","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"3746_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1046\/j.1365-2710.2003.00528.x","volume":"28","author":"E Yukawa","year":"2003","unstructured":"Yukawa E, Nonaka T, Yukawa M, Higuchi S, Kuroda T, Goto Y (2003) Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients. J Clin Pharm Ther 28(6):497\u2013504","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"3746_CR9","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ejps.2009.09.017","volume":"38","author":"K Vu\u010di\u0107evi\u0107","year":"2009","unstructured":"Vu\u010di\u0107evi\u0107 K, Miljkovi\u0107 B, Pokrajac M, Prostran M, Martinovi\u0107 \u017d, Grabnar I (2009) The influence of drug\u2013drug interaction and patients\u2019 characteristics on valproic acid\u2019s clearance in adults with epilepsy using nonlinear mixed effects modeling. Eur J Pharm Sci 38(5):512\u2013518","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"3746_CR10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.5414\/CPP48767","volume":"48","author":"S Jankovic","year":"2010","unstructured":"Jankovic S, Milovanovic J, Jankovic S (2010) Factors influencing valproate pharmacokinetics in children and adults. Int J Clin Pharmacol Ther 48(11):767","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3746_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10928-013-9323-3","volume":"40","author":"M Ibarra","year":"2013","unstructured":"Ibarra M, V\u00e1zquez M, Fagiolino P, Derendorf H (2013) Sex related differences on valproic acid pharmacokinetics after oral single dose. J Pharmacokinet Pharmacodyn 40:479\u2013486","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"3746_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/FTD.0000000000000100","volume":"37","author":"W-w Lin","year":"2015","unstructured":"Lin W-w, Jiao Z, Wang C-l, Wang H-y, Ma C-l, Huang P-f, Guo X-z, Liu Y-w (2015) Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen. Ther Drug Monit 37(1):76\u201383","journal-title":"Ther Drug Monit"},{"issue":"6","key":"3746_CR13","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.clinthera.2017.04.005","volume":"39","author":"J Methaneethorn","year":"2017","unstructured":"Methaneethorn J (2017) Population pharmacokinetics of valproic acid in patients with mania: implication for individualized dosing regimens. Clin Ther 39(6):1171\u20131181. https:\/\/doi.org\/10.1016\/j.clinthera.2017.04.005","journal-title":"Clin Ther"},{"issue":"4","key":"3746_CR14","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1007\/s11096-019-00864-w","volume":"41","author":"S Alqahtani","year":"2019","unstructured":"Alqahtani S, Alandas N, Alsultan A (2019) Estimation of apparent clearance of valproic acid in adult Saudi patients. Int j clin pharm-net 41(4):1056\u20131061","journal-title":"Int j clin pharm-net"},{"key":"3746_CR15","doi-asserted-by":"publisher","unstructured":"Teixeira-da-Silva P, P\u00e9rez-Blanco JS, Santos-Buelga D, Otero MJ, Garc\u00eda MJ (2022) Population pharmacokinetics of valproic acid in pediatric and adult Caucasian patients. Pharmaceutics 14(4):811. https:\/\/doi.org\/10.3390\/pharmaceutics14040811","DOI":"10.3390\/pharmaceutics14040811"},{"issue":"3","key":"3746_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00228-021-03246-2","volume":"78","author":"YN Zang","year":"2022","unstructured":"Zang YN, Guo W, Niu MX, Bao S, Wang Q, Wang Y, Dong F, Li AN, Ruan CJ (2022) Population pharmacokinetics of valproic acid in adult Chinese patients with bipolar disorder. Eur J Clin Pharmacol 78(3):405\u2013418. https:\/\/doi.org\/10.1007\/s00228-021-03246-2","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"3746_CR17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bcp.13510","volume":"84","author":"J Methaneethorn","year":"2018","unstructured":"Methaneethorn J (2018) A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol 84(5):816\u2013834. https:\/\/doi.org\/10.1111\/bcp.13510","journal-title":"Br J Clin Pharmacol"},{"key":"3746_CR18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00228-003-0699-7","volume":"59","author":"ES El Desoky","year":"2004","unstructured":"El Desoky ES, Fuseau E, EL Din Amry S, Cosson V (2004) Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients. Eur J Clin Pharmacol 59:783\u2013790","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"3746_CR19","doi-asserted-by":"publisher","first-page":"e111066","DOI":"10.1371\/journal.pone.0111066","volume":"9","author":"N Ogusu","year":"2014","unstructured":"Ogusu N, Saruwatari J, Nakashima H, Noai M, Nishimura M, Deguchi M, Oniki K, Yasui-Furukori N, Kaneko S, Ishitsu T (2014) Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of \u03b3-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis. PLoS ONE 9(11):e111066","journal-title":"PLoS ONE"},{"issue":"5","key":"3746_CR20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/FTD.0b013e31811f3296","volume":"29","author":"AK Birnbaum","year":"2007","unstructured":"Birnbaum AK, Ahn JE, Brundage RC, Hardie NA, Conway JM, Leppik IE (2007) Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. Ther Drug Monit 29(5):571\u2013575","journal-title":"Ther Drug Monit"},{"issue":"5","key":"3746_CR21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/17512433.2022.2075849","volume":"15","author":"Y-N Zang","year":"2022","unstructured":"Zang Y-N, Guo W, Dong F, Li A-N, de Leon J, Ruan C-J (2022) Published population pharmacokinetic models of valproic acid in adult patients: a systematic review and external validation in a Chinese sample of inpatients with bipolar disorder. Expert Rev Clin Pharmacol 15(5):621\u2013635. https:\/\/doi.org\/10.1080\/17512433.2022.2075849","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"3746_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3999\/jscpt.29.489","volume":"29","author":"K TANIKAWA","year":"1998","unstructured":"TANIKAWA K, MATSUMOTO Y, MATSUMOTO M, FUKUOKA M, YAMAMOTO R, ENDO K, SAWACHI T, NAKAMURA T (1998) Population pharmacokinetic parameters of valproic acid; conventional and slow release formulation. Rinsho yakuri\/Jpn J Clin Pharmacol Ther 29(3):489\u201394","journal-title":"Rinsho yakuri\/Jpn J Clin Pharmacol Ther"},{"issue":"10","key":"3746_CR23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1358\/mf.2007.29.10.1116313","volume":"29","author":"S Jankovic","year":"2007","unstructured":"Jankovic S, Milovanovic J (2007) Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients. Methods Find Exp Clin Pharmacol 29(10):673\u2013680","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"3","key":"3746_CR24","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1136\/ejhpharm-2018-001653","volume":"27","author":"J Methaneethorn","year":"2020","unstructured":"Methaneethorn J, Lohitnavy M (2020) External evaluation of a published population pharmacokinetic model of valproic acid in Thai manic patients. Eur J Hosp Pharm 27(3):168\u2013172. https:\/\/doi.org\/10.1136\/ejhpharm-2018-001653","journal-title":"Eur J Hosp Pharm"},{"issue":"8","key":"3746_CR25","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s11095-022-03273-3","volume":"39","author":"L Yang","year":"2022","unstructured":"Yang L, Yang N, Yi B, Pei Q, Huang Z (2022) Population pharmacokinetic evaluation with external validation of tacrolimus in Chinese primary nephrotic syndrome patients. Pharm Res 39(8):1907\u20131920. https:\/\/doi.org\/10.1007\/s11095-022-03273-3","journal-title":"Pharm Res"},{"issue":"2","key":"3746_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143\u2013151. https:\/\/doi.org\/10.1208\/s12248-011-9255-z","journal-title":"AAPS J"},{"issue":"2","key":"3746_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets E, Brendel K, Mentr\u00e9 F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 90(2):154\u2013166","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"3746_CR28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/ALN.0000000000002968","volume":"132","author":"SD Gumbert","year":"2020","unstructured":"Gumbert SD, Kork F, Jackson ML, Vanga N, Ghebremichael SJ, Wang CY, Eltzschig HK (2020) Perioperative acute kidney injury. Anesthesiology 132(1):180\u2013204. https:\/\/doi.org\/10.1097\/ALN.0000000000002968","journal-title":"Anesthesiology"},{"issue":"2","key":"3746_CR29","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s12028-022-01630-z","volume":"38","author":"G De Vlieger","year":"2023","unstructured":"De Vlieger G, Meyfroidt G (2023) Kidney dysfunction after traumatic brain injury: pathophysiology and general management. Neurocrit Care 38(2):504\u2013516. https:\/\/doi.org\/10.1007\/s12028-022-01630-z","journal-title":"Neurocrit Care"},{"key":"3746_CR30","doi-asserted-by":"crossref","unstructured":"Patsalos PN (2022) Valproic Acid. In: Patsalos PN (ed) Antiseizure Medication Interactions: A Clinical Guideed. Springer International Publishing, pp 261\u2013267","DOI":"10.1007\/978-3-030-82790-8_63"},{"issue":"9","key":"3746_CR31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/bdd.636","volume":"29","author":"T Correa","year":"2008","unstructured":"Correa T, Rodriguez I, Romano S (2008) Population pharmacokinetics of valproate in Mexican children with epilepsy. Biopharm Drug Dispos 29(9):511\u2013520. https:\/\/doi.org\/10.1002\/bdd.636","journal-title":"Biopharm Drug Dispos"},{"issue":"11","key":"3746_CR32","doi-asserted-by":"publisher","first-page":"e111066","DOI":"10.1371\/journal.pone.0111066","volume":"9","author":"N Ogusu","year":"2014","unstructured":"Ogusu N, Saruwatari J, Nakashima H, Noai M, Nishimura M, Deguchi M, Oniki K, Yasui-Furukori N, Kaneko S, Ishitsu T, Nakagaswa K (2014) Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of \u03b3-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis. PLoS ONE 9(11):e111066. https:\/\/doi.org\/10.1371\/journal.pone.0111066","journal-title":"PLoS ONE"},{"issue":"3","key":"3746_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0212-8","volume":"54","author":"J Ding","year":"2015","unstructured":"Ding J, Wang Y, Lin W, Wang C, Zhao L, Li X, Zhao Z, Miao L, Jiao Z (2015) A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. Clin Pharmacokinet 54(3):305\u2013317. https:\/\/doi.org\/10.1007\/s40262-014-0212-8","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"3746_CR34","doi-asserted-by":"publisher","first-page":"e0238201","DOI":"10.1371\/journal.pone.0238201","volume":"15","author":"YJ Tseng","year":"2020","unstructured":"Tseng YJ, Huang SY, Kuo CH, Wang CY, Wang KC, Wu CC (2020) Safety range of free valproic acid serum concentration in adult patients. PLoS ONE 15(9):e0238201. https:\/\/doi.org\/10.1371\/journal.pone.0238201","journal-title":"PLoS ONE"},{"issue":"2\u20133","key":"3746_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.14712\/23362936.2017.11","volume":"118","author":"M \u0160\u00edma","year":"2017","unstructured":"\u0160\u00edma M, Hartinger J, Rul\u00ed\u0161ek J, \u0160achl R, Slana\u0159 O (2017) Meropenem-induced valproic acid elimination: a case report of clinically relevant drug interaction. Prague Med Rep 118(2\u20133):105\u2013109. https:\/\/doi.org\/10.14712\/23362936.2017.11","journal-title":"Prague Med Rep"},{"issue":"4","key":"3746_CR36","first-page":"315","volume":"63","author":"D Bates","year":"2010","unstructured":"Bates D, Parkins M, Duggan K (2010) Ertapenem-induced reduction in valproate levels: case report and review of the literature. Can j hosp pharm 63(4):315\u2013322","journal-title":"Can j hosp pharm"},{"issue":"3","key":"3746_CR37","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.kjms.2016.12.001","volume":"33","author":"CR Huang","year":"2017","unstructured":"Huang CR, Lin CH, Hsiao SC, Chen NC, Tsai WC, Chen SD, Lu YT, Chuang YC (2017) Drug interaction between valproic acid and carbapenems in patients with epileptic seizures. Kaohsiung J Med Sci 33(3):130\u2013136. https:\/\/doi.org\/10.1016\/j.kjms.2016.12.001","journal-title":"Kaohsiung J Med Sci"},{"issue":"5","key":"3746_CR38","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/ftd.0000000000000316","volume":"38","author":"CC Wu","year":"2016","unstructured":"Wu CC, Pai TY, Hsiao FY, Shen LJ, Wu FL (2016) The effect of different carbapenem antibiotics (Ertapenem, Imipenem\/Cilastatin, and Meropenem) on serum valproic acid concentrations. Ther Drug Monit 38(5):587\u2013592. https:\/\/doi.org\/10.1097\/ftd.0000000000000316","journal-title":"Ther Drug Monit"},{"key":"3746_CR39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jcrc.2020.12.005","volume":"62","author":"IL Chen","year":"2021","unstructured":"Chen IL, Lee CH, Hsiao SC, Shih FY (2021) Interactions between carbapenems and valproic acid among the patients in the intensive care units. J Crit Care 62:151\u2013156. https:\/\/doi.org\/10.1016\/j.jcrc.2020.12.005","journal-title":"J Crit Care"},{"issue":"2","key":"3746_CR40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejpn.2014.12.010","volume":"19","author":"MC Miranda Herrero","year":"2015","unstructured":"Miranda Herrero MC, Alcaraz Romero AJ, EscuderoVilaplana V, Fern\u00e1ndezLafever SN, Fern\u00e1ndez-Llamazares CM, BarredoValderrama E, V\u00e1zquez L\u00f3pez M, de Castro P (2015) Pharmacological interaction between valproic acid and carbapenem: what about levels in pediatrics? Eur J Paediatr Neurol 19(2):155\u2013161. https:\/\/doi.org\/10.1016\/j.ejpn.2014.12.010","journal-title":"Eur J Paediatr Neurol"},{"key":"3746_CR41","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejps.2018.06.033","volume":"122","author":"S Xu","year":"2018","unstructured":"Xu S, Chen Y, Zhao M, Guo Y, Wang Z, Zhao L (2018) Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors. Eur J Pharm Sci 122:170\u2013178. https:\/\/doi.org\/10.1016\/j.ejps.2018.06.033","journal-title":"Eur J Pharm Sci"},{"issue":"10","key":"3746_CR42","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1111\/j.1745-7254.2007.00704.x","volume":"28","author":"D-c Jiang","year":"2007","unstructured":"Jiang D-c, Wang L, Wang Y-q, Li L, Lu W, Bai X-r (2007) Population pharmacokinetics of valproate in Chinese children with epilepsy. Acta Pharmacol Sin 28(10):1677\u20131684","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"3746_CR43","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3390\/pharmaceutics15020569","volume":"15","author":"S Wang","year":"2023","unstructured":"Wang S, Yin Q, Yang M, Cheng Z, Xie F (2023) External evaluation of population pharmacokinetic models of methotrexate for model-informed precision dosing in pediatric patients with acute lymphoid leukemia. Pharmaceutics 15(2):569. https:\/\/doi.org\/10.3390\/pharmaceutics15020569","journal-title":"Pharmaceutics"},{"issue":"8","key":"3746_CR44","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00228-023-03511-6","volume":"79","author":"S Wei","year":"2023","unstructured":"Wei S, Chen J, Zhao Z, Mei S (2023) External validation of population pharmacokinetic models of vancomycin in postoperative neurosurgical patients. Eur J Clin Pharmacol 79(8):1031\u20131042. https:\/\/doi.org\/10.1007\/s00228-023-03511-6","journal-title":"Eur J Clin Pharmacol"},{"key":"3746_CR45","doi-asserted-by":"publisher","unstructured":"Buclin T, Thoma Y, Widmer N, Andr\u00e9 P, Guidi M, Csajka C, Decosterd LA (2020) The steps to therapeutic drug monitoring: a structured approach illustrated with imatinib. Front Pharmacol 11. https:\/\/doi.org\/10.3389\/fphar.2020.00177","DOI":"10.3389\/fphar.2020.00177"},{"key":"3746_CR46","unstructured":"Winter ME (2011) Basic clinical pharmacokinetics: Fifth edition."},{"key":"3746_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/00003088-198005010-00002","volume":"5","author":"R Gugler","year":"1980","unstructured":"Gugler R, von Unruh GE (1980) Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 5:67\u201383","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"3746_CR48","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E (2008) Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Comm Ther Strat Epilepsia 49(7):1239\u20131276. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01561.x","journal-title":"ILAE Comm Ther Strat Epilepsia"},{"issue":"3","key":"3746_CR49","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/jalm\/jfaa181","volume":"6","author":"D Wang","year":"2021","unstructured":"Wang D, Champion-Lyons E, Neyens R, Bohm N, Caddell B, Babic N (2021) The effect of sample handling on free valproic acid levels. J Appl Lab Med 6(3):645\u2013653. https:\/\/doi.org\/10.1093\/jalm\/jfaa181","journal-title":"J Appl Lab Med"},{"issue":"3","key":"3746_CR50","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4212\/cjhp.3179","volume":"75","author":"T Brar","year":"2022","unstructured":"Brar T, Mahmoud SH (2022) Role of free valproic acid levels in a patient with severe hypoalbuminemia: a case report. Can J Hosp Pharm 75(3):239\u2013242. https:\/\/doi.org\/10.4212\/cjhp.3179","journal-title":"Can J Hosp Pharm"},{"issue":"10","key":"3746_CR51","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s40262-022-01171-w","volume":"61","author":"K Lin","year":"2022","unstructured":"Lin K, Cao VFS, Au C, Dahri K (2022) Clinical pharmacokinetic monitoring of free valproic acid levels: a systematic review. Clin Pharmacokinet 61(10):1345\u20131363. https:\/\/doi.org\/10.1007\/s40262-022-01171-w","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"3746_CR52","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00228-018-2440-6","volume":"74","author":"S Mei","year":"2018","unstructured":"Mei S, Feng W, Zhu L, Li X, Yu Y, Yang W, Gao B, Wu X, Fang F, Zhao Z (2018) Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model. Eur J Clin Pharmacol 74(8):1029\u20131036. https:\/\/doi.org\/10.1007\/s00228-018-2440-6","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"3746_CR53","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00228-009-0712-x","volume":"65","author":"D Jiang","year":"2009","unstructured":"Jiang D, Bai X, Zhang Q, Lu W, Wang Y, Li L, M\u00fcller M (2009) Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. Eur J Clin Pharmacol 65(12):1187\u20131193. https:\/\/doi.org\/10.1007\/s00228-009-0712-x","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03746-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03746-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03746-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T06:05:51Z","timestamp":1728281151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03746-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3746"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03746-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received approval from the Ethics Committee of Beijing Tiantan Hospital, Capital Medical University (KY2022-018\u201302). Informed consent was obtained from the patients or legal guardians in accordance with the guidelines of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all parents or guardians in writing.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}